Visanne (Dienogest 2mg) Regulatory Post Marketing Surveillance Study in Korea
Phase of Trial: Phase IV
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Dienogest (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Adverse reactions
- Sponsors Bayer
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Planned End Date changed from 30 Jun 2017 to 14 Jul 2017.
- 19 Jun 2017 Planned primary completion date changed from 30 Jun 2017 to 14 Jul 2017.